Medical Editor: John P. Cunha, DO, FACOEP
Neuac (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is a combination of an antibiotic and an antibacterial and drying agent indicated for the topical treatment of inflammatory acne vulgaris. Common side effects of Neuac Gel include:
- skin redness,
- burning, and
Neuac Gel should be applied once daily, in the evening or as directed by the physician, to affected areas after the skin is gently washed, rinsed with warm water and patted dry. Neuac Gel may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Neuac Gel; it is unknown if it would harm a fetus. It is unknown if Neuac Gel passes into breast milk after topical application. Oral clindamycin appears in breast milk. Because of the potential for adverse reactions in nursing infants, breastfeeding while using Neuac Gel is not recommended.
Our Neuac (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following adverse reaction is described in more detail in the WARNINGS AND PRECAUTIONS section of the label:
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. During clinical trials, 397 subjects used clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% once daily for 11 weeks for the treatment of moderate to moderately severe facial acne vulgaris. All subjects were graded for facial local skin reactions (erythema, peeling, burning, and dryness) on the following scale: 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. The percentage of subjects that had symptoms present before treatment (at baseline) and during treatment is presented in Table 1.
|% of Subjects Using Clindamycin Phossphate and Benzoyl Peroxide Gel,1.2%/5% with Symptom Present|
|Before Treatment (baseline)||During Treatment|
(Percentages derived by number of subjects receiving clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% with symptom score/number of enrolled subjects receiving clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%).
The following adverse reactions have been identified during post approval use of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%. Urticaria, application site reactions, including discoloration have been reported.
Read the entire FDA prescribing information for Neuac (Clindamycin Phosphate And Benzoyl Peroxide Gel)
© Neuac Patient Information is supplied by Cerner Multum, Inc. and Neuac Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.